Title |
Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor
|
---|---|
Published in |
BMC Veterinary Research, May 2014
|
DOI | 10.1186/1746-6148-10-105 |
Pubmed ID | |
Authors |
Charles HC Halsey, Daniel L Gustafson, Barbara J Rose, Amber Wolf-Ringwall, Robert C Burnett, Dawn L Duval, Anne C Avery, Douglas H Thamm |
Abstract |
Mast cell tumors (MCTs) are the most common skin tumors in dogs and exhibit variable biologic behavior. Mutations in the c-kit proto-oncogene are associated with the tumorigenesis of MCTs, resulting in growth factor-independent and constitutive phosphorylation of the KIT receptor tyrosine kinase (RTK). Toceranib (TOC) phosphate (Palladia®) is a KIT RTK inhibitor that has biological activity against MCTs. Despite these benefits, patients ultimately develop resistance to TOC. Therefore, there is a need to identify distinguishing clinical and molecular features of resistance in this population. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 33% |
Spain | 2 | 33% |
Unknown | 2 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 6 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 1% |
Czechia | 1 | 1% |
Brazil | 1 | 1% |
Unknown | 70 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 12 | 16% |
Student > Postgraduate | 10 | 14% |
Researcher | 9 | 12% |
Student > Master | 9 | 12% |
Professor | 4 | 5% |
Other | 14 | 19% |
Unknown | 15 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Veterinary Science and Veterinary Medicine | 26 | 36% |
Medicine and Dentistry | 16 | 22% |
Agricultural and Biological Sciences | 8 | 11% |
Biochemistry, Genetics and Molecular Biology | 2 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Other | 4 | 5% |
Unknown | 15 | 21% |